



Immunomodulatory Vaccines against Autoimmune Diseases

Guest Editor:

Dr. Maria Anagnostouli

Director of Multiple Sclerosis & Demyelinating Diseases Unit and Immunogenetics Laboratory, 1st Department of Neurology of Medical School, National and Kapodistrian University of Athens, Aeginition University Hospital, Vas. Sofias Ave 74, 115 28 Athens, Greece

Deadline for manuscript submissions:
closed (15 October 2022)

Message from the Guest Editor

Dear Colleagues,

Vaccination makes a huge contribution to preventing many infectious diseases and reducing the associated morbidity and mortality. It is a key pillar of an effective health care system. However, there is not much research on vaccination and autoimmune diseases. On the other hand, autoimmune diseases are often treated with immunotherapy. Whether vaccines are equally effective for each treatment requires further clarification.

This Special Issue will focus on recent advances in autoimmune diseases and immunomodulatory vaccines. Based on your extensive knowledge and experience in the field, we cordially invite you to participate in this Special Issue.

Dr. Maria Anagnostouli
Guest Editor





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious
Diseases, College of Veterinary
Medicine, University of Georgia,
Athens, GA 30602-7387, USA

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Author Benefits

Open Access: free for readers, with **article processing charges (APC)** paid by authors or their institutions.

High Visibility: indexed within **Scopus**, **SCIE (Web of Science)**, **PubMed**, **PMC**, **Embase**, **CAPLus / SciFinder**, and **other databases**.

Journal Rank: JCR - Q2 (Medicine, Research and Experimental) / CiteScore - Q1 (Pharmacology (medical))

Contact Us

Vaccines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/vaccines
vaccines@mdpi.com
[X@Vaccines_MDPI](https://twitter.com/Vaccines_MDPI)